NewAmsterdam Pharma (NAMS) Competitors $16.06 -0.36 (-2.19%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$16.08 +0.02 (+0.09%) As of 04/15/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. ROIV, LNTH, TGTX, RVMD, BBIO, LEGN, BPMC, SRPT, KRYS, and AXSMShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Roivant Sciences (ROIV), Lantheus (LNTH), TG Therapeutics (TGTX), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Krystal Biotech (KRYS), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Roivant Sciences Lantheus TG Therapeutics Revolution Medicines BridgeBio Pharma Legend Biotech Blueprint Medicines Sarepta Therapeutics Krystal Biotech Axsome Therapeutics NewAmsterdam Pharma (NASDAQ:NAMS) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking. Do insiders & institutionals have more ownership in NAMS or ROIV? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor NAMS or ROIV? In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 9 articles in the media. Roivant Sciences' average media sentiment score of 1.26 beat NewAmsterdam Pharma's score of 0.53 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is NAMS or ROIV more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. NewAmsterdam Pharma's return on equity of 0.00% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Roivant Sciences -119.54%-14.05%-12.81% Do analysts rate NAMS or ROIV? NewAmsterdam Pharma presently has a consensus price target of $43.33, suggesting a potential upside of 169.82%. Roivant Sciences has a consensus price target of $17.50, suggesting a potential upside of 73.96%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, NAMS or ROIV? NewAmsterdam Pharma has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Does the MarketBeat Community favor NAMS or ROIV? Roivant Sciences received 27 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.43% of users gave NewAmsterdam Pharma an outperform vote while only 78.26% of users gave Roivant Sciences an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes2796.43% Underperform Votes13.57%Roivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% Which has better earnings and valuation, NAMS or ROIV? Roivant Sciences has higher revenue and earnings than NewAmsterdam Pharma. Roivant Sciences is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56M38.71-$176.94M-$2.60-6.18Roivant Sciences$122.59M58.56$4.35B-$0.15-67.07 SummaryNewAmsterdam Pharma beats Roivant Sciences on 9 of the 17 factors compared between the two stocks. Remove Ads Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80B$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-6.186.7921.7317.81Price / Sales38.71225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book4.595.866.464.00Net Income-$176.94M$141.86M$3.20B$247.23M7 Day Performance1.26%4.50%2.85%1.45%1 Month Performance-31.28%-12.65%-8.55%-6.24%1 Year Performance-17.64%-11.06%10.46%0.60% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma2.2646 of 5 stars$16.06-2.2%$43.33+169.8%-18.6%$1.80B$45.56M-6.184Short Interest ↑ROIVRoivant Sciences2.6317 of 5 stars$9.26-2.1%$17.50+89.0%-7.2%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading VolumeLNTHLantheus4.3411 of 5 stars$95.45+5.0%$129.43+35.6%+70.6%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.3148 of 5 stars$37.25-0.3%$40.67+9.2%+177.4%$5.87B$329.00M-372.46290Positive NewsRVMDRevolution Medicines3.8147 of 5 stars$31.40+0.3%$65.23+107.7%+2.2%$5.84B$742,000.00-8.75250Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.5716 of 5 stars$30.67-2.2%$52.64+71.6%+32.9%$5.83B$221.90M-10.76400Analyst ForecastGap DownLEGNLegend Biotech2.409 of 5 stars$30.25-5.5%$79.00+161.2%-34.8%$5.56B$627.24M-31.841,070Positive NewsGap UpBPMCBlueprint Medicines2.6341 of 5 stars$80.20-1.8%$124.95+55.8%-4.4%$5.13B$508.82M-74.26640Positive NewsHigh Trading VolumeSRPTSarepta Therapeutics4.6725 of 5 stars$52.40-3.7%$163.18+211.4%-54.0%$5.08B$1.90B41.92840Short Interest ↑Gap DownHigh Trading VolumeKRYSKrystal Biotech4.6447 of 5 stars$166.01-3.1%$220.00+32.5%-0.4%$4.93B$290.52M55.52210AXSMAxsome Therapeutics4.5823 of 5 stars$98.50-0.4%$169.80+72.4%+52.2%$4.82B$385.69M-16.44380Analyst Revision Remove Ads Related Companies and Tools Related Companies Roivant Sciences Alternatives Lantheus Alternatives TG Therapeutics Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives Blueprint Medicines Alternatives Sarepta Therapeutics Alternatives Krystal Biotech Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAMS Stock Free NAMS Stock Alerts